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Background
New insights into genetic characteristics of 
leukemic cells have initiated the 
development of the chimeric antigen 
receptor (CAR) T-cell therapy. This type of 
adoptive cell immunotherapy has been a 
breakthrough in the treatment of aggressive 
B-cell lymphoma and B-cell precursor acute 
lymphoblastic leukemia. (NIH)
CAR T cells are constructed by harvesting 
mononuclear cells. These cells are usually 
acquired from a patient’s own blood.  T cells 
are altered genetically or chemically to 
express a transgene encoded with a tumor-
specific CAR.  The altered CAR T cells are 
reinfused into the patient to multiple and 
eradicate tumor cells. 
Previous CAR T therapies have mixed 
outcomes.
The development of CD27-CARs to target 
CD70 shows promising increased safety for 
CAR- T cell immunotherapy.
Results
Developed CD27- CARs to target CD70 to 
promote tumor eradicate
CD70 proteins are highly expressed in T-
cell Lymphoma and Leukemia such as AML
CD27-CARs are viral particles formulated 
by infecting host organisms.  Particles are 
functionalized by genetic and chemical 
manufacturing. The construction of 
lentiviral vectors constructed from plasmids 
into 293T cells trough transformation, 
transfection, and transduction.
The measurement of the viral titration 
showed MOI (multiplicity of infection) to be 
at its highest at 48 hours. Bi-functional 
CAR-T cells show increased safety for 
CAR- t cell immunotherapy and enhanced 
movement against cancer target antigens to 
promote tumor eradication. 
.
Conclusions
CAR-T treatment for patients with blood 
tumors has shown promising outcomes.  
Further study is needed.  The optimization of 
protocols to generate CAR-T cells has the 
potential to improve the quality of cells and 
thus, therapies. 
The immunotherapeutic treatment of 
immunocompromised patients with CAR T 
cells is one of the most encouraging adoptive 
cellular therapy tactics to date in the treatment 
of leukemia and lymphoma. Promoting the 
progression of CAR therapies will further 
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Nanodrop 2000 is used to quantify and asses
the purification of DNA, RNA, protein. In 
these graphs the results were low excluding 
the last test with the results 258.83 (Nucleic 
Acid) and 1.8 (260/280). With low results 
means the CD70 protein needs to be tested 
with a midiprep protocol
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Methods
We tested the efficacy of CD27- CARs to 
target CD70. Through the transformation of 
27CAR plasmids in a competent E-coli cell. 
CD27 functional activity was assessed 
through the generation of 27- CAR viral 
particles by transfection. The measurement 
of viral titration was examined through 
Flow cytometry test. Following, the 
isolation of CD70 plasmid DNA from 
selected clones allows for the desired 
plasmid to be confirmed through RE 
(restriction enzyme) digestion. Thus, 
allowing for a ligand/ receptor 
communication between CD27 and CD70 
and the generation of CAR T cells.
-Transform 27CAR plasmids in a competent 
E.Coli cells
-isolate plasmid DNA from selected clones
-confirm RE Digestion
-Generate 27- CAR viral particles by 
transfection
-measure viral titer
-Generate CAR- T cells
The protein encoded by this gene is a 
cytokine that belongs to the tumor 
necrosis factor (TNF) ligand family. This 
cytokine is a ligand for CD27. It is a 
surface antigen on activated 
lymphocytes. It induces proliferation of 
costimulated T cells, enhances the 
generation of cytolytic T cells, and 
contributes to T cell activation. This 
cytokine is also reported to play a role in 
regulating B-cell activation,
cytotoxic function of natural killer cells, 
and immunoglobulin sythesis. (provided 














1 258.83 1.127 0.582 1.8 2.4 DNA 50.00





260/280 260/230 A280 Sample 
Type
Factor
1 4.6 0.058 1.58 0.50 0.058 DNA 50.00
2 2.8 0.032 1.66 0.87 0.033 DNA 50.00
3 75.5 0.863 1.81 2.19 0.836 DNA 50.00
4 33.8 0.384 1.76 1.84 0.384 DNA 50.00
5 12.3 0.131 1.88 1.69 0.131 DNA 50.00
6 5.4 0.058 1.88 0.80 0.058 DNA 50.00
7 17.3 0.387 0.90 0.84 0.387 DNA 50.00
CD70 antigen to CD27 ligand
